| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
GPR40 (free fatty acid receptor 1); PPARγ (weak ligand); TLR4 (inflammatory signaling); fatty acid-binding proteins (FABPs).
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
Palmitic acid activates GPR40 and weakly binds PPARγ, and it serves as a ligand for FABPs. In SH-SY5Y neuroblastoma cells, palmitic acid up-regulates TLR4 expression, promotes TLR4 recruitment to membrane lipid rafts, and potentiates resistin-induced NF-κB activation and inflammatory cytokine (IL-6, TNF-α) expression. |
| ln Vivo |
In vivo, elevated palmitic acid levels in obesity promote inflammation and insulin resistance through TLR4-dependent signaling. Palmitic acid is also a major substrate for energy metabolism and is incorporated into triglycerides and phospholipids. The deuterated form is used as a tracer to quantify palmitic acid absorption, distribution, and oxidation.
|
| Enzyme Assay |
GPR40 activation is measured by calcium mobilization or cAMP assays in GPR40-expressing cells. TLR4 signaling is assessed by NF-κB reporter assays or cytokine ELISA in macrophages treated with palmitic acid (50–500 µM). Binding to FABPs is measured by fluorescence displacement assays.
|
| Cell Assay |
In vitro cell experiments use macrophages, SH-SY5Y neuroblastoma cells, or hepatocytes. Cells are treated with palmitic acid (50–500 µM) complexed to bovine serum albumin, and inflammatory cytokine release, NF-κB activation, and insulin signaling (Akt/ERK phosphorylation) are measured.
|
| Animal Protocol |
Rodent studies administer palmitic acid-d2-3 by oral gavage or intravenous infusion, often as part of a high-fat diet or lipid emulsion. Plasma and tissue samples are collected for lipidomic analysis by LC-MS/MS or GC-MS using the deuterated internal standard to quantify palmitic acid and its metabolites.
|
| References |
| Molecular Formula |
C16H32O2
|
|---|---|
| Molecular Weight |
258.436408996582
|
| Exact Mass |
258.253
|
| CAS # |
83293-32-7
|
| Related CAS # |
Palmitic acid;57-10-3
|
| PubChem CID |
101029267
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.552
|
| tPSA |
37.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
18
|
| Complexity |
178
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)O
|
| InChi Key |
IPCSVZSSVZVIGE-FNHLFAINSA-N
|
| InChi Code |
InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)/i14D2
|
| Chemical Name |
3,3-dideuteriohexadecanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8694 mL | 19.3469 mL | 38.6937 mL | |
| 5 mM | 0.7739 mL | 3.8694 mL | 7.7387 mL | |
| 10 mM | 0.3869 mL | 1.9347 mL | 3.8694 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.